Endogenous ligands at sites of vascular injury

Endogenous ligands at sites of vascular injury refers to a diverse collection of molecules that become accessible to the blood following endothelial disruption (Ruggeri, Z. M., Nature Medicine, 2002). These include subendothelial matrix components such as collagen and von Willebrand factor (vWF), which are critical for initial platelet tethering and adhesion (PubMed, PMID: 15141010). Additionally, tissue factor (TF) is exposed on the surface of damaged cells or adventitial fibroblasts, acting as the primary initiator of the extrinsic coagulation cascade (Mackman, N., Blood, 2006). Soluble ligands like adenosine diphosphate (ADP) and thromboxane A2 (TXA2) are subsequently released from activated platelets to amplify the thrombotic response (Davì, G., & Patrono, C., NEJM, 2007). While these ligands are essential for physiological hemostasis, their uncontrolled exposure in atherosclerotic plaques leads to pathological thrombosis, causing myocardial infarction and stroke (StatPearls, Physiology, Hemostasis). Therapeutic strategies involve blocking the receptors for these ligands, such as P2Y12 or GPIIb/IIIa, or inhibiting the enzymes responsible for their synthesis, like cyclooxygenase-1 (PubChem, Aspirin).

Other names

Subendothelial matrix componentsProthrombotic mediatorsVascular damage-associated molecular patternsHemostatic triggers

Drugs typically act by inhibiting the receptors for these ligands (e.g., P2Y12 receptor antagonists), inhibiting the enzymes that produce them (e.g., COX-1 inhibitors), or directly neutralizing the ligands or their downstream coagulation factors (e.g., Factor Xa inhibitors).